Mtor Pathway | Topics

Articles tagged with Mtor Pathway

JCI table of contents: Aug. 21, 2008

Simultaneous inhibition of two signaling pathways, mTOR and MAPK, resulted in enhanced antitumor effects in mouse models of prostate and breast cancer. This combination therapy may improve the treatment of human cancers, particularly for patients with advanced, hormone-refractory prostate cancer.

Cancer therapy: A role for MAPK inhibitors combined with mTORC1 inhibitors

Research led by Beth Israel Deaconess Medical Center identifies a previously unrecognized problem faced by mTORC1 inhibitors: activating the MAPK pathway, which encourages cancer cell survival. Scientists found that combining mTORC1 and MAPK inhibitors may offer a new treatment option for cancer patients.

1 2